Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 6
- Countries
- 0
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8487129 | PYLARIFYpiflufolastat f-18 | substance, product | Nov 2027 |
| 12070513 | PYLARIFYpiflufolastat f-18 | substance, product | Jul 2029 |
| 9861713 | PYLARIFYpiflufolastat f-18 | substance, product | Jul 2029 |
| 8778305 | PYLARIFYpiflufolastat f-18 | substance, product | Sept 2030 |
| 10947197 | PYLARIFYpiflufolastat f-18 | substance, product | Jun 2037 |
| 11851407 | PYLARIFYpiflufolastat f-18 | substance, product | Jun 2037 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| PYLARIFY | PIFLUFOLASTAT F-18 | injection, intravenous | 71258-022NDA |
Compare
Other companies listing piflufolastat f-18
- Aphelion LLC0 sites · 1 NDC
Enquiry
Common questions
- Is Progenics Pharmaceuticals, Inc. FDA approved?
- Progenics Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Progenics Pharmaceuticals, Inc. make?
- 1 product is listed under Progenics Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as injection. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.